References
- Andius P, Johansson SL, Holman S (2007). Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology, 70, 758-62. https://doi.org/10.1016/j.urology.2007.06.638
- Bryan RT, Zeegers MP, James ND, Wallace DM, Cheng KK (2010). Biomarkers in bladder cancer. BJU Int, 105, 608-13. https://doi.org/10.1111/j.1464-410X.2009.08880.x
- Chen JX, Deng N, Chen X et al (2012). A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev, 13, 2229-34. https://doi.org/10.7314/APJCP.2012.13.5.2229
- Cho KS, Seo HK, Joung JY et al (2009). Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer. J Urol, 182, 2625-30. https://doi.org/10.1016/j.juro.2009.08.083
- Csoka AB, Frost GI, Stern R (2001). The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol, 20, 499-508. https://doi.org/10.1016/S0945-053X(01)00172-X
- Dalbagni G, Parekh DJ, Ben-Porat L, et al (2007). Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int, 99, 281-5. https://doi.org/10.1111/j.1464-410X.2006.06624.x
- Ding MX, Wang HF, Wang JS et al (2012). ppGalNAc T1 as a potential novel marker for human bladder cancer. Asian Pac J Cancer Prev, 13, 5653-7. https://doi.org/10.7314/APJCP.2012.13.11.5653
- Eissa S, Kassim SK, Labib RA et al (2005). Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer, 103, 1356-62. https://doi.org/10.1002/cncr.20902
- Ekici S, Cerwinka WH, Duncan R et al (2004). Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6, and microvessel density for prostate cancer. Int J Cancer, 112, 121-9. https://doi.org/10.1002/ijc.20368
- Ghafouri-Fard S, Nekoohesh L, Motevaseli E (2014). Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev, 15, 2395-403. https://doi.org/10.7314/APJCP.2014.15.6.2395
- Gomez CS, Gomez P, Knapp J et al (2009). Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol, 182, 1350-6. https://doi.org/10.1016/j.juro.2009.06.070
- Habuchi T, Marberger M, Droller MJ et al (2005). Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology, 66, 64-74. https://doi.org/10.1016/j.urology.2005.08.065
- Heney NM (1992). Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am, 19, 429-33.
- Herr HW, Donat SM, Dalbagni G (2007). Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol, 177, 75-9. https://doi.org/10.1016/j.juro.2006.08.070
- Huang YJ, Qi WX, He AN et al (2013). Prognostic Value of Tissue Vascular Endothelial Growth Factor Expression in Bladder Cancer: a Meta-analysis. Asian Pac J Cancer Prev, 14, 645-9. https://doi.org/10.7314/APJCP.2013.14.2.645
- Kirkali Z, Chan T, Manoharan M et al (2005). Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology, 66, 4-34. https://doi.org/10.1016/S0090-4295(05)00945-3
- Kramer MW, Golshani R, Merseburger AS et al (2010). HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol, 57, 86-93. https://doi.org/10.1016/j.eururo.2009.03.057
- Kramer MW, Escudero DO, Lokeshwar SD et al (2011). Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer, 117, 1197-209. https://doi.org/10.1002/cncr.25565
- Lascombe I, Clairotte A, Fauconnet S et al (2006). N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors. Clin Cancer Res, 12, 2780-7. https://doi.org/10.1158/1078-0432.CCR-05-2387
- Lokeshwar VB, Rubinowicz D, Schroeder GL et al (2001). Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem, 276, 11922-32. https://doi.org/10.1074/jbc.M008432200
- Lokeshwar VB, Young MJ, Goudarzi G et al (1999). Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res, 59, 4464-70.
- Lokeshwar VB, Cerwinka WH, Lokeshwar BL (2005). HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res, 65, 2243-50. https://doi.org/10.1158/0008-5472.CAN-04-2805
- Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL (2005). HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res, 65, 7782-9.
- Lopez-Knowles E, Hernandez S, Kogevinas M et al (2006). The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res, 15, 6029-36.
- Nieder AM, Brausi M, Lamm D et al (2005). Management of stage T1 tumors of the bladder. International Consensus Panel. Urology, 66, 108-25.
- Posey JT, Soloway MS, Ekici S et al (2003). Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res, 63, 2638-44.
- Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA (2004). Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol, 45, 292-6. https://doi.org/10.1016/j.eururo.2003.10.006
- Shariat SF, Karam JA, Lerner SP (2008). Molecular markers in bladder cancer. Curr Opin Urol, 18, 1-8. https://doi.org/10.1097/MOU.0b013e3282f1c5c1
- Simpson MA, Lokeshwar VB (2008). Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci, 13, 5664-80.
- Srivastava AK, Singh PK, Srivastava K et al (2013). Diagnostic role of survivin in urinary bladder cancer. Asian Pac J Cancer Prev, 14, 81-5. https://doi.org/10.7314/APJCP.2013.14.1.81
- Stein JP, Penson DF (2008). Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int, 102, 270-5. https://doi.org/10.1111/j.1464-410X.2008.07743.x
- Tuna B, Yorukoglu K, Tuzel E et al (2003). Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract, 199, 323-8. https://doi.org/10.1078/0344-0338-00424
- Wang HF, Wang JS (2012). Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer. Asian Pac J Cancer Prev, 13, 1723-6. https://doi.org/10.7314/APJCP.2012.13.5.1723
Cited by
- Evaluation and screening of mRNA S100A genes as serological biomarkers in different stages of bladder cancer in Egypt vol.37, pp.4, 2016, https://doi.org/10.1007/s13277-015-4264-7